Silver Book Fact

In one study, Alzheimer’s patients who took donepezil had an increase in their prescription costs of $1,000 per patient, but saw reduced total medical costs of about 1/3–from $11,947 to $8,056.

Hill, Jerrold W., Robert Futterman, Vera Mastey, and Howard Fillit. The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan. Manag Care Interface. 2002; 15(3): 63-70. http://www.ncbi.nlm.nih.gov/pubmed/11925682

Reference

Title
The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan
Publication
Manag Care Interface
Publication Date
2002
Authors
Hill, Jerrold W., Robert Futterman, Vera Mastey, and Howard Fillit
Volume & Issue
Volume 15, Issue 3
Pages
63-70
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • An Alzheimer’s disease treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce Medicaid costs for people with the disease by $14 billion in 2020–from…  
  • Impact of a 5-Year Delay in Onset by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050  
  • A clinical trial in Europe found that treating Alzheimer’s patients with an Alzheimer’s drug reduced annual treatment costs by $1,000 per patient.  
  • Medicines Allow Patients to Remain Independent Longer: New Alzheimer’s medicine delays need for costly home care  
  • Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.